Alpha Cognition Inc
ACOG
Rang in aandelen
#20080
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Aandeelprijs
$8.66
Marktkapitalisatie
$134.50M
Verandering (1 dag)
1.88%
Verandering (1 jaar)
72.17%
Land
US
Handel Alpha Cognition Inc (ACOG)
Categorie
Healthcare
P/B-ratio voor Alpha Cognition Inc (ACOG)
P/B-ratio op October 2026 TTM: -114.63
Volgens de meest recente financiële rapporten en aandelenkoers van Alpha Cognition Inc is de huidige P/B-ratio (TTM) -114.63. Eind 2022 had het bedrijf een P/B-ratio van -274.94.
P/B-ratiohistoriek voor Alpha Cognition Inc van 2018 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | -114.63 | -53.90% |
| 2023 | -248.67 | -9.55% |
| 2022 | -274.94 | -288.08% |
| 2021 | 146.19 | -97.93% |
| 2020 | 7.05K | 6,164.26% |
| 2019 | 112.47 | 16.25% |
| 2018 | 96.75 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 6.251 | -105.45% |
US
|
|
| 13.2547 | -111.56% |
US
|
|
| 4.208 | -103.67% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -105.39% |
NL
|
